Carlo Maria Barbagallo

List of Publications by Year
in descending order

52	1,134	394421 19	434195 31
papers	citations	h-index	g-index

52	52	52	1286
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. European Journal of Preventive Cardiology, 2022, 29, 1501-1509.	1.8	9
2	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. Journal of Nephrology, 2022, 35, 211-221.	2.0	34
3	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. Journal of Human Hypertension, 2022, 36, 976-982.	2.2	20
4	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1245-1252.	2.6	15
5	Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients. Atherosclerosis, 2022, 347, 63-67.	0.8	5
6	Comparison of two polygenic risk scores to identify non-monogenic primary hypocholesterolemias in a large cohort of Italian hypocholesterolemic subjects. Journal of Clinical Lipidology, 2022, 16, 530-537.	1.5	3
7	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. Clinical Research in Cardiology, 2021, 110, 1073-1082.	3.3	31
8	Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. Life, 2021, 11, 315.	2.4	8
9	Lack of phenotypic additive effect of familial defective apolipoprotein B3531 in familial hypercholesterolaemia. Internal Medicine Journal, 2021, 51, 585-590.	0.8	1
10	rs629301 CELSR2 polymorphism confers a ten-year equivalent risk of critical stenosis assessed by coronary angiography. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1542-1547.	2.6	7
11	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. Frontiers in Cardiovascular Medicine, 2021, 8, 713652.	2.4	18
12	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 62-69.	0.5	49
13	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 333-340.	0.5	46
14	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension, 2020, 75, 302-308.	2.7	177
15	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. Journal of Hypertension, 2020, 38, 412-419.	0.5	70
16	Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?. Cardiovascular Research, 2018, 114, 1595-1604.	3.8	9
17	Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing. Journal of Clinical Lipidology, 2017, 11, 272-281.e8.	1.5	18
18	Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterolâ€“diabetes connection? A systematic review of literature. Acta Diabetologica, 2017, 54, 111-122.	2.5	19

#	Article	IF	Citations
19	Myristic acid is associated to low plasma HDL cholesterol levels in a Mediterranean population and increases HDL catabolism by enhancing HDL particles trapping to cell surface proteoglycans in a liver hepatoma cell model. Atherosclerosis, 2016, 246, 50-56.	0.8	16
20	Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic endâ€stage renal disease patients. Hemodialysis International, 2015, 19, 360-367.	0.9	5
21	Role of Nutraceuticals in Hypolipidemic Therapy. Frontiers in Cardiovascular Medicine, 2015, 2, 22.	2.4	22
22	Dietary strategy for prevention and management of dyslipidemia: international guidelines. Mediterranean Journal of Nutrition and Metabolism, 2012, 5, 187-193.	0.5	0
23	Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study. Acta Diabetologica, 2012, 49, 145-151.	2.5	10
24	Novel LMF1 Nonsense Mutation in a Patient with Severe Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4584-4590.	3.6	52
25	Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia. Atherosclerosis, 2009, 206, 193-198.	0.8	22
26	The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: Results of a 15 years follow-up in a Mediterranean population. Atherosclerosis, 2008, 197, 147-153.	0.8	42
27	Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thrombosis and Haemostasis, 2007, 98, 1362-1367.	3.4	15
28	Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. Metabolism: Clinical and Experimental, 2006, 55, 662-668.	3.4	19
29	Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. Metabolism: Clinical and Experimental, 2006, 55, 1308-1316.	3.4	15
30	Cystatin C levels are decreased in acute myocardial infarction. International Journal of Cardiology, 2005, 101, 213-217.	1.7	28
31	Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: A one-year follow-up study. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 361-367.	2.6	11
32	Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. European Journal of Endocrinology, 2004, 150, 831-836.	3.7	0
33	Effects on Lipoprotein Subclasses of Combined Expression of Human Hepatic Lipase and Human apoB in Transgenic Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 141-146.	2.4	37
34	Beta-2-glycoprotein I is growth regulated and plays a role as survival factor for hepatocytes. International Journal of Biochemistry and Cell Biology, 2004, 36, 1297-1305.	2.8	8
35	Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. Clinica Chimica Acta, 2003, 328, 91-97.	1.1	3
36	No association between Glu298Asp endothelial nitric oxide synthase polymorphism and Italian sporadic Alzheimer's disease. Neuroscience Letters, 2003, 341, 229-232.	2.1	25

#	Article	IF	Citations
37	Nutritional Characteristics of a Rural Southern Italy Population: The Ventimiglia di Sicilia Project. Journal of the American College of Nutrition, 2002, 21, 523-529.	1.8	30
38	Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction. American Journal of Cardiology, 2002, 89, 460-462.	1.6	17
39	Determinants of enhanced thromboxane biosynthesis in renal transplantation. Kidney International, 2001, 59, 1574-1579.	5.2	20
40	Overexpression of Human Hepatic Lipase and ApoE in Transgenic Rabbits Attenuates Response to Dietary Cholesterol and Alters Lipoprotein Subclass Distributions. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 625-632.	2.4	33
41	Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome. Kidney International, 1999, 55, 2433-2439.	5.2	15
42	Rapid screening of the LDL receptor point mutation FH-Genoa/Palermo. , 1999, 13, 412-412.		2
43	CAROTID ATHEROSCLEROSIS IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 1999, 67, 366-371.	1.0	37
44	Influence of ApoE Content on Receptor Binding of Large, Buoyant LDL in Subjects With Different LDL Subclass Phenotypes. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 466-472.	2.4	8
45	Lipoprotein Profile and High-Density Lipoproteins: Subfractions Distribution in Centenarians. Gerontology, 1998, 44, 106-110.	2.8	22
46	Plasma Lipid, Apolipoprotein and Lp(a) Levels in Elderly Normolipidemic Women: Relationships with Coronary Heart Disease and Longevity. Gerontology, 1995, 41, 260-266.	2.8	23
47	Plasma levels of lipoproteins and apolipoproteins in congenital hypothyroidism: Effects of l-thyroxine substitution therapy. Metabolism: Clinical and Experimental, 1995, 44, 1283-1287.	3.4	10
48	A new case of apo C-II deficiency with a nonsense mutation in the apo C-II gene. Clinica Chimica Acta, 1994, 224, 111-118.	1.1	7
49	Follow-Up of Lipid and Apoprotein Levels in Renal Transplant Recipients. Nephron, 1991, 58, 255-256.	1.8	10
50	Apolipoprotein profile in type II diabetic patients with and without coronary heart disease. Acta Diabetologica Latina, 1990, 27, 371-377.	0.2	10
51	Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis: A comparison with type IV hyperlipoproteinemic patients. Metabolism: Clinical and Experimental, 1989, 38, 601-602.	3.4	18
52	Diagnostic use of fructosamine assay in the control of type II diabetes mellitus. Acta Diabetologica Latina, 1988, 25, 63-68.	0.2	3